Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

Min S. Park, Shreyaskumar R. Patel, Joseph A. Ludwig, Jonathan Trent, Charles A. Conrad, Alexander J. Lazar, Wei Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S. Benjamin, Dejka M. Araujo

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

BACKGROUND: Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m 2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven patients (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14%) had stable disease as the best response, and 1 patient (7%) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.

Original languageEnglish
Pages (from-to)4939-4947
Number of pages9
JournalCancer
Volume117
Issue number21
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

temozolomide
Solitary Fibrous Tumors
Disease-Free Survival
Therapeutics
Poisons
Sarcoma
Bevacizumab
Malignant Hemangiopericytoma
Neoplasms
Tomography

Keywords

  • anti-angiogenesis inhibitors
  • chemotherapy
  • hemangiopericytoma
  • soft tissue sarcoma
  • solitary fibrous tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. / Park, Min S.; Patel, Shreyaskumar R.; Ludwig, Joseph A.; Trent, Jonathan; Conrad, Charles A.; Lazar, Alexander J.; Wang, Wei Lien; Boonsirikamchai, Piyaporn; Choi, Haesun; Wang, Xuemei; Benjamin, Robert S.; Araujo, Dejka M.

In: Cancer, Vol. 117, No. 21, 01.11.2011, p. 4939-4947.

Research output: Contribution to journalArticle

Park, MS, Patel, SR, Ludwig, JA, Trent, J, Conrad, CA, Lazar, AJ, Wang, WL, Boonsirikamchai, P, Choi, H, Wang, X, Benjamin, RS & Araujo, DM 2011, 'Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor', Cancer, vol. 117, no. 21, pp. 4939-4947. https://doi.org/10.1002/cncr.26098
Park, Min S. ; Patel, Shreyaskumar R. ; Ludwig, Joseph A. ; Trent, Jonathan ; Conrad, Charles A. ; Lazar, Alexander J. ; Wang, Wei Lien ; Boonsirikamchai, Piyaporn ; Choi, Haesun ; Wang, Xuemei ; Benjamin, Robert S. ; Araujo, Dejka M. / Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. In: Cancer. 2011 ; Vol. 117, No. 21. pp. 4939-4947.
@article{978825a926524f359d19c8d01f7d9307,
title = "Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor",
abstract = "BACKGROUND: Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m 2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven patients (79{\%}) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14{\%}) had stable disease as the best response, and 1 patient (7{\%}) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6{\%}. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.",
keywords = "anti-angiogenesis inhibitors, chemotherapy, hemangiopericytoma, soft tissue sarcoma, solitary fibrous tumors",
author = "Park, {Min S.} and Patel, {Shreyaskumar R.} and Ludwig, {Joseph A.} and Jonathan Trent and Conrad, {Charles A.} and Lazar, {Alexander J.} and Wang, {Wei Lien} and Piyaporn Boonsirikamchai and Haesun Choi and Xuemei Wang and Benjamin, {Robert S.} and Araujo, {Dejka M.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1002/cncr.26098",
language = "English",
volume = "117",
pages = "4939--4947",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "21",

}

TY - JOUR

T1 - Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

AU - Park, Min S.

AU - Patel, Shreyaskumar R.

AU - Ludwig, Joseph A.

AU - Trent, Jonathan

AU - Conrad, Charles A.

AU - Lazar, Alexander J.

AU - Wang, Wei Lien

AU - Boonsirikamchai, Piyaporn

AU - Choi, Haesun

AU - Wang, Xuemei

AU - Benjamin, Robert S.

AU - Araujo, Dejka M.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - BACKGROUND: Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m 2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven patients (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14%) had stable disease as the best response, and 1 patient (7%) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.

AB - BACKGROUND: Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m 2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven patients (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14%) had stable disease as the best response, and 1 patient (7%) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.

KW - anti-angiogenesis inhibitors

KW - chemotherapy

KW - hemangiopericytoma

KW - soft tissue sarcoma

KW - solitary fibrous tumors

UR - http://www.scopus.com/inward/record.url?scp=79961219491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961219491&partnerID=8YFLogxK

U2 - 10.1002/cncr.26098

DO - 10.1002/cncr.26098

M3 - Article

C2 - 21480200

AN - SCOPUS:79961219491

VL - 117

SP - 4939

EP - 4947

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 21

ER -